Nebius: The $25 Million-a-Megawatt Mirage

NBIS   Daily · data to 2026-11-12 close · 10 SMA 20 SMA 50 SMA 150 SMA RS vs Nasdaq
Frozen at publication – this chart does not move. Open live chart on TradingView →

Nebius posted 571% revenue growth to $907M and guided to $12-13B for 2027, yet the stock fell 16.8%. Management dodged questions on prepayments, customer concentration, and CapEx. The real story: soaring demand but mounting cash burn and evasive answers. Is the AI infrastructure darling running out of runway?

Inside the Full Analysis

  • 🔒Record Growth, Record Questions
  • 🔒The Missing Metrics: What Nebius Didn’t Tell You
  • 🔒When Confidence Cracks: Script vs. Reality
  • 🔒Evasion Tactics: The Hot Seat Moments
  • 🔒Excuses vs. Execution: The Blame Game
  • 🔒The CAN SLIM Check
  • 🔒Conclusion


Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice. Always verify against primary filings before making any investment decision.

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.